Viva BioInnovator is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas ranging from our focus on biopharmaceuticals to interests in devices, diagnostics, and life science tools.
By leveraging Viva Biotech’s rich experience and technical advantages in novel drug R&D, we provide both cash and in-kind services, also called Equity-for-Services (EFS), for our investments.
We can also work with start-ups through our incubation track which offers value-added services in operations, logistical support, and more to support early-stage development.
Click below to learn more about our our in-kind services.
Viva BioInnovator works with some of the world’s brightest minds to help discover novel and life-changing therapeutics. We can assist our portfolio companies through several avenues, including CRO and CDMO services, financial support, access to experts, industry networks, back-office operations, and more.
We are continuously on the lookout for innovative ideas and set no restrictions on indication, drug type, or company location. All companies we invest in have access to capital and expert guidance, but for a very select few companies, Viva BioInnovator can act as a hands-on incubator to assist in company creation and development. Selected portfolio companies can choose what support they would like to receive from the Investment and Incubation tracks.
Above all else, our priority is to be a Partner for founders with innovative ideas. We can help grow their ideas into clinical success and treat debilitating diseases. By work together towards a shared goal, we can provide this support through two tracks:
Catalyze Innovation and Growth
Each Portfolio company will have the option to receive a Venture Partner for management support and a Venture Advisor for scientific consultation.
Although our focus is early-stage start-ups, we help our portfolio companies make new connections for later-stage funding and financial advice.
We host an annual Partnership Summit and multiple Demo Days throughout the year to help our portfolio companies connect with a broader ranger of investors and potential development partners.
We can introduce Chinese investors for later-stage funding opportunities.
We can provide assistance in procuring internal or external resources that may be critical for development and refer trusted CROS.
We will alert founders to changes in market dynamics.
We can provide China market introductions for out-licensing, development of China rights, and more.
Viva Biotech’s leading CRO platform is productive and efficient to enable both quick and quality drug candidate discovery. Our portfolio companies can access Viva’s elite CRO teams through our Equity-for-Service investments
Companies that choose to utilize Viva Biotech’s world-leading drug discovery platform can reach PCC within three years, drastically accelerating their milestone achievement.
Viva Biotech’s services range from target identification to CMC.
Realize the '0 to 1' Transformation
Above all else, our priority is to be a Partner for founders with innovative ideas. We can help grow their ideas into clinical success and to treat debilitating diseases. By work together towards a shared goal, we can provide this support through 2 tracks:
VBI can assist in the registration and formation of new companies in China and the United States.
We have innovative partnership models to work with relevant collaborators such as setting up spin-outs, JVs, risk-sharing models, and more. We’re also always open to hearing new ideas for how we can work with great founders and good partners.
We can help procure lab and office space through our locations in Shanghai, Jiaxing, Chengdu, and Hangzhou.
We can provide virtual back office support for HR, accounting, procurement, and BD.
VBI can assist with candidate interviews and assessments.
We excel in helping our portfolio companies with their long-term strategic planning.